Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile

Clicks: 3
ID: 317150
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #342 of 531 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 531 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: VH4524184 (VH-184) is an emerging third-generation integrase strand transfer inhibitor (INSTI) with an enhanced in vitro resistance profile compared with second-generation INSTIs being developed as a long-acting antiretroviral therapy (ART) for HIV-1. We present data from a proof-of-concept phase 2a trial of VH-184 in people with HIV-1. METHODS: This randomized, double-blind, placebo-controlled trial evaluated oral VH-184 monotherapy in adults naive to ART with HIV-1 RNA ≥3000 copies/mL. Participants received oral VH-184 10, 50, or 300 mg or placebo on Days 1 (baseline), 4, and 7. On Day 10, participants initiated standard-of-care ART. The primary endpoint was maximum change from baseline in plasma HIV-1 RNA through Day 10. Secondary endpoints included safety, tolerability, exposure-response relationship, CD4+ cell effects, and treatment-emergent resistance. RESULTS: Of 22 participants enrolled (VH-184, n=19; placebo, n=3), 86% were male, 68% were White, and median age was 32 years. Mean maximum change from baseline through Day 10 in HIV-1 RNA was -1.17, -2.15, and -2.31 log10 copies/mL for VH-184 10, 50, and 300 mg, respectively. No adverse events (AEs) leading to withdrawal, treatment-emergent serious AEs, or deaths occurred. There were no clinically relevant changes in safety laboratory parameters, electrocardiograms, or vital signs. No VH-184 genotypic or phenotypic resistance was detected through Day 10. CONCLUSIONS: VH-184 monotherapy demonstrated rapid and potent antiviral activity and a favorable safety and tolerability profile. The established exposure-response model and efficacy and safety results support further development of VH-184 as the core agent in complete ART regimens for HIV-1 (ClinicalTrials.gov, NCT06214052).
Reference Key
openalex_W7164496023 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Luise Rogg, Sebastián A. Núñez, M V Mingrone, Peré Domingo, Charlotte-Paige Rolle, Robert Güerri‐Fernández, Vicente Estrada, Mónica López, Nathan Hanan, Gabriela Ghita, Jerry L Jeffrey, Mark Underwood, José Castillo‐Mancilla, Fiona Halliday, Ebele Ezeadi, Martin Gartland
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag357
URL
https://doi.org/10.1093/cid/ciag357
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.